Modern treatment of vulvar cancer.
lymphoscintigraphy
radiotherapy
sentinel lymph node biopsy
surgical treatment
vulvar cancer
Journal
Radiology and oncology
ISSN: 1581-3207
Titre abrégé: Radiol Oncol
Pays: Poland
ID NLM: 9317213
Informations de publication
Date de publication:
22 09 2020
22 09 2020
Historique:
received:
28
06
2020
accepted:
21
07
2020
pubmed:
23
9
2020
medline:
17
8
2021
entrez:
22
9
2020
Statut:
epublish
Résumé
Background Vulvar cancer accounts for 3-5% of malignant diseases of the female genital tract. The Slovenian incidence rate is 5.5/100,000, which means 57 new cases per year. The most common histological type (90%) is squamous cell carcinoma. Based on etiology, it can be classified into the first type which correlates with human papillomavirus (HPV) infection and the second type which is not associated with HPV. The most common and long-lasting symptom of vulvar cancer is pruritus. The preferred diagnostic procedure to confirm the diagnosis is a punch or incision biopsy. Surgery in combination with radiotherapy is the standard treatment for vulvar cancer. Sentinel lymph node biopsy with lymphoscintigraphy is now a standard part of surgical treatment. Chemotherapy is a palliative treatment option. Conclusions Vulvar cancer is a rare disease. Because of the pathogenesis, surgery and radiotherapy are the main treatment modalities. The sentinel node biopsy (SNB) represents a contemporary approach to the vulvar cancer treatment and significantly reduces morbidity. Improvements in treatment of vulvar cancer contributed to the decrease of mortality among Slovenian women.
Identifiants
pubmed: 32960779
doi: 10.2478/raon-2020-0053
pii: /j/raon.ahead-of-print/raon-2020-0053/raon-2020-0053.xml
pmc: PMC7585347
doi:
pii:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
371-376Références
Int J Gynecol Cancer. 2017 Oct;27(8):1769-1773
pubmed: 28763369
Wien Klin Wochenschr. 2013 Mar;125(5-6):119-28
pubmed: 23519539
Gynecol Oncol. 2010 Apr;117(1):82-7
pubmed: 20092880
Histopathology. 2013 Jan;62(1):161-75
pubmed: 23190170
Int J Gynecol Cancer. 2015 Jul;25(6):1086-93
pubmed: 25768079
Int J Gynecol Cancer. 2017 May;27(4):832-837
pubmed: 28441255
Radiol Oncol. 2017 Feb 22;51(1):47-55
pubmed: 28265232
Gynecol Oncol. 2013 Oct;131(1):113-7
pubmed: 23932893
Gynecol Oncol. 2016 Mar;140(3):415-9
pubmed: 26797295
Gynecol Oncol. 2015 Aug;138(2):472-7
pubmed: 26022527
Gynecol Oncol Case Rep. 2012 Jul 27;2(4):119-20
pubmed: 24371640
Gynecol Oncol. 2019 Jun;153(3):574-579
pubmed: 30876675
Obstet Gynecol. 2016 Oct;128(4):754-60
pubmed: 27607871
J Dtsch Dermatol Ges. 2019 Dec;17(12):1257-1276
pubmed: 31829526
Cancer Manag Res. 2018 Jan 09;10:61-68
pubmed: 29386916
Gynecol Oncol. 2012 Oct;127(1):141-6
pubmed: 22750258
Wien Klin Wochenschr. 2017 Nov;129(21-22):805-809
pubmed: 28884278
Cancer Imaging. 2015 Jun 10;15:8
pubmed: 26059775
Int J Womens Health. 2015 Mar 20;7:305-13
pubmed: 25848321
J Clin Oncol. 2008 Feb 20;26(6):884-9
pubmed: 18281661
Clin Obstet Gynecol. 2020 Mar;63(1):12-23
pubmed: 31855904
Cancer Cytopathol. 2019 Aug;127(8):514-520
pubmed: 31174235
Int J Gynecol Cancer. 2010 Feb;20(2):294-8
pubmed: 20169671
Lancet Oncol. 2014 Jan;15(1):23-34
pubmed: 24314615
Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1060-1078
pubmed: 31680701
Medicine (Baltimore). 2017 Nov;96(46):e8722
pubmed: 29145314
Gynecol Oncol. 2017 Jul;146(1):87-93
pubmed: 28506563
Best Pract Res Clin Obstet Gynaecol. 2015 Aug;29(6):812-21
pubmed: 25962357